Abstract
One vaccine to prevent cervical cancer could be available in just months and another may come next year as regulatory agencies begin their reviews of the two candidates. Both vaccines use virus-like particles (VLPs) to block infection with human papillomavirus (HPV) types 16 and 18, which cause most cervical cancers ( seebox , p. 432).

This publication has 0 references indexed in Scilit: